Mabpharm's strong revenue growth may be causing investors to overvalue the stock. If this growth doesn't surpass the broader industry, the stock could be overpriced. The high P/S ratio may not be sustainable without significant medium-term trend improvements.
邁博薬業に関するコメント
まだコメントはありません